Bevacizumab in the Treatment of Advanced, Non-Squamous Non-Small Cell Lung Cancer: An Evidence-Based Approach

Publisher： Karger

E-ISSN： 1423-0232|80|5-6|350-358

ISSN： 0030-2414

Source： Oncology, Vol.80, Iss.5-6, 2011-07, pp. : 350-358

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Bevacizumab in combination with different platinum‐based doublets in the first‐line treatment for advanced nonsquamous non‐small‐cell lung cancer: A network meta‐analysis

By  

INTERNATIONAL JOURNAL OF CANCER, Vol. 142, Iss. 8, 2018-04 ,pp. : 1676-1688

John Wiley & Sons Inc

Access to resources Recommend Favorite

An indirect comparison of the efficacy of bevacizumab plus carboplatin and paclitaxel versus pemetrexed with cisplatin in patients with advanced or recurrent non-squamous adenocarcinoma non-small cell lung cancer

By Nuijten Mark J.C.   Aultman Rick   Carpeño Javier de Castro   Vergnenègre Alain   Chouaid Christos   Walzer Stefan   Siebert Uwe  

Current Medical Research and Opinion, Vol. 27, Iss. 11, 2011-11 ,pp. : 2193-2201

Informa Healthcare

Access to resources Recommend Favorite

Erlotinib versus Pemetrexed for Pretreated Non-Squamous Non-Small Cell Lung Cancer Patients in Clinical Practice

By  

Oncology, Vol. 84, Iss. 5, 2013-02 ,pp. : 255-264

Karger

Access to resources Recommend Favorite

Maximizing Benefits from Maintenance Pemetrexed with Stereotactic Ablative Radiotherapy in Oligoprogressive Non-Squamous Non-Small Cell Lung Cancer

By  

Case Reports in Oncology, Vol. 9, Iss. 2, 2016-08 ,pp. : 474-480

Karger

Access to resources Recommend Favorite

Smoking History as a Predictor of Pemetrexed Monotherapy in Patients with Non-Squamous Non-Small Cell Lung Cancer

By  

Oncology, Vol. 91, Iss. 1, 2016-05 ,pp. : 41-47

Karger

Access to resources Recommend Favorite